<DOC>
	<DOCNO>NCT00003966</DOCNO>
	<brief_summary>RATIONALE : Giving defibrotide may effective treatment liver damage may result follow peripheral stem cell transplantation . PURPOSE : This randomized phase II trial study defibrotide see well work treat patient severe liver disease undergoing peripheral stem cell transplantation .</brief_summary>
	<brief_title>Defibrotide Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate post-hematopoietic stem cell transplant patient severe veno-occlusive disease liver treat defibrotide . - Determine minimal effective dose drug patient . - Assess toxicity adverse side effect drug patient . OUTLINE : This randomize , multicenter study . All patient initially receive dose defibrotide IV 2 hour every 6 hour day 1 . On day 2 , patient randomize 1 2 dos defibrotide . - Arm I : On day 2-14 , patient receive low dose defibrotide IV 2 hour every 6 hour . - Arm II : On day 2-14 , patient receive high dose defibrotide IV 2 hour every 6 hour . In arm , course repeat every 14 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 140 patient ( 70 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Defibrotide</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis VOD define : Jaundice ( bilirubin ≥ 2 mg/dL ) 2 follow : ascites , weight gain &gt; 5 % baseline weight ( see Section 5.2 ) , hepatomegaly , RUQ pain Patients jaundice reversal flow Doppler examination portal vein eligible one following : ascites , weight gain &gt; 5 % baseline weight , hepatomegaly , RUQ pain Patients preexist hepatomegaly must documentation physical exam image liver size increase baseline admission Patients meet criterion Section 3.1.1 ( ie . two major criterion three ) biopsy proven VOD eligible presence characteristic consistent severe disease ( see ) . Patients concurrent , confound cause liver dysfunction clinically evident evident ultrasound radiographic imaging ( evidence biliary ductal dilatation focal tissue defect ) may require biopsyproven VOD and/or elevate wedged transhepatic venous pressure gradient measurement ( ≥10 mm mercury ) consider eligible . Best medical judgment image study use clarify diagnosis determine confound cause liver dysfunction . Severity VOD define : For patient addressed Bearman model ( i.e . within 16 day SCT condition either BU/CY , CY/TBI CBV ) , must 30 % great risk severe VOD ( see Appendix B ) . For patient addressed Bearman model ( ie . beyond 16 day SCT and/or condition either BU/CY , CY/TBI CBV ) , must concomitant multiorgan failure define presence one following : renal dysfunction : ) creatinine ≥2x value date admission day BMT unit condition ≥2x low value conditioning ( use low value calculation ) , b ) creatinine clearance GFR ≤50 % admission value , c ) dialysis dependence '' pulmonary dysfunction : documentation oxygenation saturation ≤ 90 % room air ; requirement positive pressure/ventilator dependence pulmonary dysfunction must attributable another cause ( e.g . document infectious pneumonia ) central nervous dysfunction : documentation confusion , lethargy , and/or delirium central nervous dysfunction must attributable another cause ( e.g . document cyclosporin toxicity ) Patients parents/guardians designate proxy must ability give voluntary inform consent protocol . Where possible , patient assent also obtain Patients must ≥ 12 hour cessation heparin Patient must eligible diagnosis VOD Day 35 post transplant Exclusion Criteria Patients receive concomitant heparin anticoagulant unless use routine CVL management , fibrinolytic instillation CVL occlusion , intermittent dialysis ultrafiltration exclude . Patients receive systemic tPA ( concomitant prior ) exclude . Patients significant uncontrolled acute bleeding , define hemorrhage require &gt; 15 cc/kg pack red blood cell ( ie . pediatric patient weigh 20 kg require &gt; 300cc pack red blood cell /24 hour adult patient weigh 70 kg require &gt; 3 unit pack red blood cells/24 hour ) replace blood loss exclude . These parameter must review prior enrollment PI his/her designate . Patients hemodynamic instability define : Hemodynamic stability define requirement pressor support OR able maintain mean arterial pressure within 1 SD ageadjusted level pressor support ( see Appendix D ) Patients require renal dose dopamine alone ( 25 mcg/kg/min ) eligible without measurement mean arterial pressure Patients Grade BD GVHD , grade accord IBMTR Severity Index ( see Appendix G ) . Please note patient Grade B skin eligible . Patients intubate documented intrinsic lung disease Patients intubate secondary mechanical barrier ventilation , e.g.pulmonary edema ascites , eligible long PaO2/FiO2 ratio ≥ 300 and/or oxygen index ( OI= { MAP x FiO2 } ÷ PaO2 x 100 ) ≤ 25 % time enrollment Patients meet Grade IV common toxicity criterion neurotoxicity ( Grade IV confusion and/or delirium ) , i.e . coma , seizure , toxic psychosis Patients currently receive treatment another experimental agent . Please note experimental agent set define drug device use IND designation associate systemic effect could influence outcome patient severe VOD . If continue use experimental agent consider necessary appropriate , must review approved case case basis Overall Study PI , Dr. Paul Richardson , designate , approve entry patient concurrently treat another experimental agent evidence potential adverse pharmacokinetic interaction overlap toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>veno-occlusive disease</keyword>
</DOC>